Organization
Department of Haematology-Oncology
5 abstracts
Abstract
Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,
Abstract
Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Haematology-Oncology, National University Cancer Institute, Mediclinic City Hospital,
Abstract
Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines.Org: Department of Haematology-Oncology, National University Cancer Institute, National University Hospital, Saw Swee Hock School of Public Health, National University of Singapore,
Abstract
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute, Mediclinic City Hospital,
Abstract
PD-L1 expression as a unique negative predictive biomarker in advanced squamous NSCLC when treated with first-line chemotherapy.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Biomedical Informatics, The Ohio State University, Department of Haematology-Oncology, National University Cancer Institute,